(Q43589900)

25 November 2017

A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction (English)

1 reference

25 November 2017

1 reference

myocardial infarction

1 reference

3

H M Krumholz

1 reference

25 November 2017

2

J H Gurwitz

1 reference

25 November 2017

4

J Avorn

1 reference

25 November 2017

S C Kalish

1

1 reference

25 November 2017

1 June 1995

1 reference

Journal of General Internal Medicine

25 November 2017

1 reference

25 November 2017

10

1 reference

25 November 2017

6

1 reference

25 November 2017

321-330

1 reference

https://scigraph.springernature.com/pub.10.1007/bf02599951

25 November 2017

0 references

cites work

Thrombolysis in acute myocardial infarction: t-PA for everyone?

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02599951

GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico

21 January 2018

1 reference

12 December 2020

Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries

1 reference

12 December 2020

Recent changes in attack and survival rates of acute myocardial infarction (1975 through 1981). The Worcester Heart Attack Study

1 reference

12 December 2020

A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method.

1 reference

12 December 2020

Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. AIMS Trial Study Group

1 reference

12 December 2020

In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group

1 reference

12 December 2020

Forecasting the effects of health reform on US physician workforce requirement. Evidence from HMO staffing patterns

1 reference

12 December 2020

Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1

1 reference

12 December 2020

More on the GUSTO trial

1 reference

12 December 2020

Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction

1 reference

12 December 2020

Incidence and case fatality rates of acute myocardial infarction (1975–1984): The Worcester Heart Attack Study

1 reference

12 December 2020

Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction

1 reference

12 December 2020

Coronary thrombolysis for the elderly?

1 reference

12 December 2020

Quality of life six months after myocardial infarction treated with thrombolytic therapy. AUS-TASK Group. Australian arm of International tPA/SK Mortality Trial

1 reference

12 December 2020

Comparison of delay times to hospital presentation for physicians and nonphysicians with acute myocardial infarction

1 reference

12 December 2020

Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model

1 reference

12 December 2020

Screening for hypertension

1 reference

12 December 2020

Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial

1 reference

12 December 2020

Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction

1 reference

12 December 2020

ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct S

1 reference

12 December 2020

A cost-effectiveness model for coronary thrombolysis/reperfusion therapy

1 reference

12 December 2020

Mortality and recurrences during eight years following stroke

1 reference

12 December 2020

Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis

1 reference

12 December 2020

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

12 December 2020

Cost effectiveness of thrombolytic treatment for myocardial infarction: comparison of anistreplase, alteplase and streptokinase in 270 patients treated within 4 hours

1 reference

12 December 2020

Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction

1 reference

12 December 2020

Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators

1 reference

12 December 2020

Thrombolytic therapy of acute myocardial infarction. Keeping the unfulfilled promises

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02599951

1 reference

PubMed ID

7562123

Dimensions Publication ID

25 November 2017

0 references

1 reference

PubMed ID

7562123